$DHR

DANAHER CORP /DE/

Danaher is a science and technology company with more than 15 operating companies organized into Biotechnology, Life Sciences and Diagnostics segments. It serves customers including pharmaceutical and biotechnology companies, research institutions, laboratories, hospitals and other healthcare providers. Its products and services support biological medicine research and manufacturing, life sciences research and drug development, filtration and purification, and disease diagnosis and treatment decisions. The Biotechnology segment offers equipment, consumables, software and services, including bioprocessing and discovery and medical solutions, marketed under brands such as CYTIVA and PALL. Life Sciences provides instruments, consumables, software and services for biological research and manufacturing, alongside filtration products, with brands including BECKMAN COULTER, IDT and SCIEX. Diagnostics sells clinical and molecular testing instruments, consumables, software and services under brands including CEPHEID, HEMOCUE and RADIOMETER. Danaher typically makes sales through direct sales personnel and independent distributors, with many products and services sold on a recurring basis. Its facilities are located in approximately 50 countries.

0
3
0
—
$13.4M
McGrew Matthew
0%
See all $DHR insider activity →
Low

Danaher Targets Faster Growth With Acquisitions, AI and a Diagnostics Push

Danaher (NYSE:DHR) has spent $11B on acquisitions this year, including Masimo and StatLab, expecting high-single-digit returns within five years. The company is also investing in AI and bioprocessing, with Cytiva targeted for long-term growth. Danaher plans opportunistic share buybacks and maintains its dividend commitment.

A Memo To Danaher's Biotechnology Team About Turning Orders Into Sales

Danaher's Biotechnology unit grew sales 7.9% in fiscal 2025, contributing 29.7% of total revenue. The company's stock trades at 38.2 times earnings. Danaher's debt increased to $26.5 billion by Q3 2026, with free cash flow rising to $5.73 billion. Bioprocessing orders grew in the mid-teens, while revenue grew in the upper end of mid-single digits. Management expects growth rates to improve in 2027.

DHR sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 3 news stories mentioning DHR (DANAHER CORP /DE/). Coverage has been balanced: 0 bullish, 3 neutral, and 0 bearish.

Recent DHR coverage spans financial news, insider activity and technology.

In the last 30 days, DHR insiders filed 6 SEC Form 4 transactions — no purchases and 6 sales ($13.4M). The most active reporter was McGrew Matthew, Executive Vice President, with 3 filings.

What's driving DHR

AlphAI scores every news story that mentions DHR with an AI model for sentiment and relevance, and aggregates insider trades from DANAHER CORP /DE/'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $DHR

Score

A Memo To Danaher's Biotechnology Team About Turning Orders Into Sales

Danaher's Biotechnology unit grew sales 7.9% in fiscal 2025, contributing 29.7% of total revenue. The company's stock trades at 38.2 times earnings. Danaher's debt increased to $26.5 billion by Q3 2026, with free cash flow rising to $5.73 billion. Bioprocessing orders grew in the mid-teens, while revenue grew in the upper end of mid-single digits. Management expects growth rates to improve in 2027.

Danaher CEO Sees Faster Growth Ahead, With AI and Acquisitions in Focus

Danaher (DHR) CEO expects faster growth driven by AI, acquisitions, and Cytiva's high-single-digit growth. The company is investing in autonomous labs and partnerships, with Cytiva specified in 90% of monoclonal antibody volume. Reshoring presents a $1B opportunity. Life sciences and diagnostics segments show improvement, with China business growing at high-single-digit rates.

Beckman Coulter receives FDA clearance for bacterial infection test

Beckman Coulter Diagnostics, part of Danaher Corporation, received FDA clearance for the Access MeMed BV assay, a blood test distinguishing bacterial from viral infections in patients aged 90 days and older. The test runs on the company's DxI 9000 and Access 2 immunoassay analyzers, providing results in 15 minutes. Developed with MeMed, the test measures immune-response proteins to generate a bacterial infection likelihood score.

Related tickers